Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in the second-line HCC treatment setting
|
|
|
|
|
|
Implement strategies to identify, monitor, and manage treatment-related AEs and improve adherence in patients with HCC
|
|
|
|
|
|
Evaluate emerging data supporting the value of biomarkers in patients with HCC
|
|
|
|
|
|